Mutational profiling of Chinese ROS1 positive non-small cell lung cancer patients with required resistant to crizotinib by next generation sequencing.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e13120
Abstract: e13120Background: The ROS1 rearrangement has been identified in 1%-2% of NSCLC cases, these patients would benefit from the inhibitor of crizotinib. But the resistance to crizotinib inevitably developed in the patients with ROS1+ NSCLC and… read more here.
Keywords: crizotinib; resistance crizotinib; mutational profiling; profiling chinese ... See more keywords